Overview

Study of AXT-1003 in Subjects with Advanced Malignant Tumors.

Status:
RECRUITING
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in patients with advanced malignancies.
Phase:
PHASE1
Details
Lead Sponsor:
Axter Therapeutics (Beijing) Co., Ltd